In August 2020, the IND for KL-A289 (anti-LAG-3 mAb) was approved by the NMPA to begin a Phase 1 clinical trial in China. LAG-3 has recently emerged as a promising therapeutic target in oncology due to its overexpression in various types of solid tumors, including melanoma, lung, colorectal, liver, and breast cancer. There is also existing literature that suggests inhibition of LAG-3 could provide synergy in tumor inhibition when combined with other immune checkpoint inhibitors, especially with anti-PD-1 antibodies. In preclinical studies, KL-A289 showed a good safety profile and demonstrated efficacy as monotherapy and in combination with checkpoint inhibitors against various tumor types, including NSCLC and CRC.
Currently, we are looking for potential partners who may be interested to collaborate on KL-A289; possible collaborations could include co-development, regional licensing, or combination therapy. For more information or interests in collaboration, please contact email@example.com.
Business Development Team
KLUS Pharma Inc.
Cranbury, New Jersey, USA